DUBLIN–(BUSINESS WIRE)–The “Global High Potency API (HPAPI) Contract Manufacturing Market(2023 Edition): Analysis By Formulation (Injectables, Oral Solids, Lotions, Others), End Use, By Region, By Country: Market Insights and Forecast (2019-2029)” report has been added to ResearchAndMarkets.com’s offering.
The Global High Potency API Contract Manufacturing Market is expected to generate USD 21.12 billion by the end of 2029, up from USD 10.89 Billion in 2022. During the forecast period, 2024-2029, the Global High Potency API Contract Manufacturing market is expected to grow at a CAGR of 10.22%.
The research report provides analysis for the historical period of 2019-2022, estimates of 2023 and the forecast period of 2024-2029. The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, Switzerland, Belgium, Spain, China, India, Japan).
HPAPI contract manufacturing is a dynamic sector of the pharmaceutical industry specialising in the production of potent and complex therapeutic compounds. HPAPIs are distinguished by their substantial potency and low therapeutic quantities, often demanding careful handling as well as manufacturing procedures to guarantee both their safety and effectiveness.
Rising healthcare expenditures, particularly in developing nations, have been a key factor in the expansion of the contract manufacturing sector due to rising HPAPI demand among the local pharmaceutical companies looking to expand their product portfolio. Governments and the private sector are making investments in R&D and improving access to advanced therapies.
Additionally, a growing number of mid-scale pharmaceutical companies is also backing the market growth, as Contract manufacturing enables them to produce such high-potency drugs without making large capital investments.
Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market’s evolution.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024 – 2029 |
| Estimated Market Value (USD) in 2024 | $12.98 Billion |
| Forecasted Market Value (USD) by 2029 | $21.12 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
Scope of the Report
- The report analyses the High Potency API Contract Manufacturing Market by Value (USD Billion).
- The report presents the analysis of High Potency API Contract Manufacturing Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
- The report analyses the High Potency API Contract Manufacturing Market by Formulation (Injectables, Oral Solids, Lotions Other Formulations).
- The report analyses the High Potency API Contract Manufacturing Market by End Use (Oncology, Antidiabetics, Autoimmune, Other End Uses).
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
Strategic Recommendations
- Geographical expansion
- Environmentally Sustainable Contract Manufacturing of HPAPI
Competitive Positioning
- Companies’ Product Positioning
- Market Position Matrix
- Market Share Analysis of HPAPI Contract Manufacturing Market
Company Profiles
- Lonza
- Catalent, Inc.
- Piramal Pharma Solutions
- Pfizer CentreOne
- Gentec Pharmaceutical Group
- AbbVie Contract Manufacturing
- Corden Pharma International
- Curia Global, Inc.
- Merck Group (SigmaAldrich Co., LLC)
- Polpharma Group
For more information about this report visit https://www.researchandmarkets.com/r/s7midi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900